Search This Blog

Tuesday, August 18, 2020

Supernus Pharmaceuticals EPS beats by $0.16, misses on revenue

Supernus Pharmaceuticals (NASDAQ:SUPN): Q2 GAAP EPS of $0.65 beats by $0.16.

Revenue of $126.73M (+21.0% Y/Y) misses by $5.27M.



Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)